The cardiorenal connection & diabetes: Exploring opportunities - - PowerPoint PPT Presentation

The cardiorenal connection & diabetes: Exploring

• pportunities for intervention
• Dr. Maria Rosa Costanzo, MD

Naperville, Illinois, USA

June 7, 2020 - Virtual ERA-EDTA

The Cardiorenal Connection & Dia iabetes: Exploring Opportunities for In Interv rvention

Maria Rosa Costanzo, M.D., F.A.H.A., F.A.C.C., F.E.S.C. Medical Director, Heart Failure Research, Advocate Heart Institute Medical Director, Edward Hospital Center for Advanced Heart Failure 801 South Washington Street Naperville, Illinois, U.S.A

Distinguishing Features of f SGL2 In Inhibitors

• Cause weight loss by exporting calories from the body to the urine
• Reduce BP commensurate to their natriuretic effect
• Are uricosuric
• Inhibition of the tubular urate transporter URAT1
• Tubular fluid glucose trans-stimulate uric acid secretion by the facilitative

glucose transporter GLUT9

• Do not cause hypoglycemia because glycosuric effect disappears

when blood glucose levels decline below 70mg/dL, as a result of transport capacity residual in SGLT1 and because the drugs leave metabolic counter-regulation intact

• Reversibly lessen GFR (i.e. reduce hyperfiltration)by activating TGF

Anticipated Effects of SGLT2 In Inhibitors on Clinical variables in T2DM Patients

David Z. Cherney et al. J Am Coll Cardiol 2019;74:2511-2524

Due to Decreased BV, Reduced Arterial Stiffness, Improved Endothelial Function

David Z. Cherney et al. J Am Coll Cardiol 2019;74:2511-2524

Selected Physiological Mechanisms Associated With Cardiovascular and Renal Protection With SGLT2 Inhibitors

SGLT2 Mechanism in in th the Early Proximal Tubule

Thomson SC, Vallon V. Am J Cardiol 2019;124:S28−S35 ✓ Normal daily GF contains 1 mol (180 mg) glucose. ✓ If all excreted in the urine, loss of energy equivalent to 30% of body’s caloric expenditure. ✓ SGLT1 and 2 can reabsorb 2.5 mol glucose/day. ✓ SGLT1 reabsorbs 2 Na per glucose; SGLT2 1 Na per glucose. ✓ SGLT2 reabsorbs 25% of Na linked to bicarbonate reabsorption. ✓ If filtered glucose rises to transport max. then the amount of Na that passes through SGLT increases to 19 mmol/L or 80% of Na directly linked to bicarbonate. ✓ Na reabsorption draws water, increasing Cl concentration and further increasing NaCl reabsorption.

Renal Outcomes in in SGLT2 In Inhib ibit itors and in in Captopril l Tria ials

Thomson SC, Vallon V. Am J Cardiol 2019;124:S28−S35

Similarity of eGFR Outcomes in SGLT2 Inhibitor Clinical Trials

Thomson SC, Vallon V. Am J Cardiol 2019;124:S28−S35

Immediate Effects of Phlorizin Delivered to Bowman’s Space on Macula De Densa De Deli livery ry of

• f Na

Na, Cl, l, Flu Fluid id Vol

• lume, an

and SNGFR Measured Do Downstream of

• f th

the Mac acula la De Densa to Allo llow TGF to Operate.

Thomson SC, Vallon V. Am J Cardiol 2019;124:S28−S35

Early Distal Tubule Flow Rate Determined by Distal Tubular Collection

Acu cute an and Chronic Effects of

• f

SG SGLT2 Blo lockade with ith Da Dapagli liflozin on

• n Tubular

Reabsorption in in a a Rodent Mod

• del of
• f Earl

arly Di Diabetes

Thomson SC, Vallon V. Am J Cardiol 2019;124:S28−S35 Intact TGF Attenuated Chronic Response due to Compensatory Reabsorption in the Loop of Henle

Media ian Change in in 24-h h Systolic ic BP and Media ian % Change in in Pla lasma Volume and Red Cell ll Mass

Lambers Heerspink HJ et al. Diabetes Obes Metab 2013;15: 853-63

Mechanis isms of In Interstit itial l and In Intravascular Volume Exp xpansion in in HF

Miller WL. Circ Heart Fail. 2016;9: e002922.

Changes in Skin Sodium Content aft fter 6 Week Treatment with SGLT2 In Inhibitors

Karg MV et al. Cardiovasc Diabetol 2018; 17:

SGLT2 and Sodium-Hydrogen Exchange

➢Co-localization and positive interference between SGLT2 and sodium-hydrogen exchanger (NHE) ➢Inhibition of SGLT2 suppresses the activity of NHE3 ➢Knocking out tubular NHE3 reduces expression of SGLT2 and the natriuretic effect of SGLT2 blockade. ➢The coupling may facilitate the GTB of sodium, glucose, and bicarbonate when GFR is increasing. ➢Acid-base balance and glucose metabolism are already coupled through phosphoenolpyruvate carboxykinase ➢(PEPCK), a key enzyme for both gluconeogenesis and the renal compensatory response for systemic acidosis. ➢Blood glucose will rise whenever tubular PEPCK is stimulated by acidosis and systemic pH will rise when PEPCK is

stimulated to perform gluconeogenesis.

➢This confounding could be mitigated by having SGLT2 and NHE3 change in parallel because increasing SGLT2 to

raise cell glucose above its equilibrium concentration would suppress

➢PEPCK and increasing NHE3 expression would sustain ammonia secretion, thereby allowing the proximal tubule

to perform its function as a regulator of systemic pH with less reliance on PEPCK

➢empagliflozin suppresses NHE1 in cardiac myocytes, which do not express SGLT2

Metabolic and Macula Densa Effects

❖SGLT2 inhibitors are ketogenic and thereby improve cardiac function (the heart

requires less oxygen when generating ATP from ketones. SGLT2 could also benefit the diabetic kidney by this same mechanism, effectively reducing regional hypoxia.

❖Blocking the macula densa nitric oxide synthase 1(NOS1) eliminates

hyperfiltration in diabetic rats while having minimal impact on GFR in nondiabetic animals.

❖Macula densa cells express SGLT1 and activating SGLT1 in MD triggers NOS1

activity.

❖New studies show knockout of SGLT1 prevents diabetes-induced upregulation of

NOS1 in the macula densa and mitigates glomerular hyperfiltration.

❖Absence of SGLT1 also attenuates upregulation of macula densa NOS1

expression in response to SGLT2 inhibition in non-diabetic mice.

❖Effects of SGLT1 and SGLT2 inhibition on diabetic glomerular hyperfiltration are

additive.

Empaglifl flozin In Increases Cardiac Energy Production in Diabetes

Areas of f Overlap for Clinical Trials wit ith SGLT2 in in Pati tients with CKD

David Z. Cherney et al. J Am Coll Cardiol 2019;74:2511-2524

All ll-Cause Mortali lity, CV Events, an and Renal l Outcomes in in CVOTs of

• f SG

SGLT-2 In Inhibit itors

➢ Reduction in albuminuria and hard renal

• utcomes:

➢ Over a wide range of baseline HgbA1c ➢ Across albuminuria ranges ➢ With and without baseline renal

impairment

➢ In DECLARE renal benefit occurred even

though renal risk was low at baseline (eGFR 85 ml/min/1.73m2)

David Z. Cherney et al. J Am Coll Cardiol 2019;74:2511-2524

All ll-Cause Mortality, CV Events, , and Renal l Outcomes in in the CREDENCE Tria ial

RENAAL (Losartan) NNT=34 Reduction in Renal Composite Outcomes 16% in RENAAL 20% in IDNT

30% Reduction in Primary Outcome

DAPA-HF HF Prim imary Endpoint Acc ccording to Pre-Specified Subgroups

Mc Murray JJV et al. N Engl J Med 2019;381:1995-2008.

Conclusions

• Patients with T2DM have high residual risk for the development of

cardiovascular complications and diabetic kidney disease progression.

• SGLT2 inhibitors have consistently reduced the risk of hospitalization

for HF and progression of diabetic kidney disease.

• Selection of antihyperglycemic agents in patients with T2DM should

take several factors into account, including metabolic requirements, safety, and background presence of CVD, HF, and renal complications.

• Ongoing and future trials are required to determine the safety and

efficacy of SGLT2 inhibitors in novel settings, including in nondiabetic adults with CVD and/or kidney disease, and in individuals with CVD in the absence of T2DM.

Heart failure with preserved ejection fraction (HFpEF) LVEF >40%1 Heart failure with reduced ejection fraction (HFrEF) LVEF ≤40%4

The empagliflozin chronic heart failure program

LVEF, left ventricular ejection fraction. 1. ClinicalTrials.gov. NCT03057951 2. Butler J et al. ESC-HF 2018; poster P972 3. ClinicalTrials.gov. NCT03057977 4. Zannad F et al. ESC-HF 2018; poster P1755 5. ClinicalTrials.gov. NCT03448406 6. Ponikowski P et al. ESC-HF 2018; poster P302 7. ClinicalTrials.gov. NCT03448419 8. Abraham WT et al. ESC-HF 2018; poster P303 9. ClinicalTrials.gov. NCT03332212

Outcomes trial with planned recruitment:

3350 patients3,4

Outcomes trial with planned recruitment:

5500 patients1,2 Functional capacity study 300 patients5,6 Functional capacity study 300 patients7,8 Mechanistic study 86 patients9